Editas Medicine, Inc. (EDIT) is a leading genetic medicine company, pioneering transformative therapies that utilize advanced genome editing technologies. Founded in 2013 and based in Cambridge, Massachusetts, Editas Medicine has positioned itself at the forefront of a revolution in medicine with a clear mandate: to translate breakthroughs in gene editing technologies, such as CRISPR and TALENs, to design and develop curative therapies that treat genetically-defined diseases.
Editas Medicine is focused on serving patients who suffer from debilitating genetic disorders which are currently untreatable. The company is built around bringing this mission to life, by developing medicines that enable precise editing of genetic material, with the aim of eliminating disease-causing abnormalities at the DNA level.
The firm’s unique approach is based on CRISPR/Cas9 and CRISPR/Cpf1 gene editing technology platforms. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized the field of genetic engineering, by enabling targeted and highly precise alterations to specific genes within an organism. This technology holds the potential not only to correct genetic defects, but also to treat a wide array of diseases, by modifying DNA sequences.
Editas Medicine is developing a diverse portfolio of treatments with the hope of improving the lives of patients across multiple therapeutic areas including ocular diseases, cancer immunotherapies, and disorders arising from viral infections.
One of Editas Medicine’s most notable programs is its research into treating Leber Congenital Amaurosis type 10 (LCA10), a rare genetic disease that leads to blindness. The company has developed EDIT-101, an experimental gene therapy, which is the first in-vivo CRISPR medicine to be administered to a patient in a clinical trial.
The global genetic medicine landscape is highly competitive and rapidly evolving, and Editas Medicine faces the challenge of both developing successful therapies and navigating regulatory complexities. Yet, with its robust research and development capabilities, and commitment to leveraging the therapeutic potential of gene-editing technologies, Editas Medicine has positioned itself as a serious contender in the race to bring genetic medicine to those who need it the most.
As at the forefront of gene-editing technology, Editas Medicine's impact on future therapies and cure of genetic disorders is significant. The company’s work could potentially rewrite the script for treating genetic diseases, affirming their dedication to transforming lives through the power of genome editing.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Editas Medicine is preparing to initiate a Phase I/II human trial for its gene-editing therapy, EDIT-401, targeting heterozygous familial hypercholesterolemia. The therapy previously achieved a 90% reduction in LDL cholesterol in nonhuman primates, an effect that lasted for 10 months. The company aims for over 60% LDL reduction in humans while prioritizing safety, with initial safety data expected in Q1 2027 and efficacy data in H2 2027.
Editas Medicine reported its third-quarter 2026 results, announcing a narrowed net loss of $0.15 per share and a cash runway extending into the second half of 2028. The company also received Australian regulatory approval to begin its Phase 1/2 Strive study for EDIT-401 in hyperlipidemia, with initial safety data expected in Q1 2027. Despite increased R&D and administrative expenses, the positive preclinical data for EDIT-401 and a milestone payment from Bristol Myers Squibb are seen as positive developments for shareholders.
EDITAS MEDICINE ($EDIT) reported its Q3 2026 earnings, surpassing analyst estimates for both earnings per share and revenue. The company posted -$0.15 per share, beating the -$0.19 estimate, and recorded revenue of $10,370,000, significantly exceeding the $4,549,118 estimate. The article also details recent insider trading activity, primarily sales, and significant increases in institutional holdings from various hedge funds.
Linda Burkly, EVP and Chief Scientific Officer at Editas Medicine, Inc., acquired 16,533 common stock shares on November 5, 2026. This acquisition resulted from the vesting of a performance-based restricted stock unit, triggered by the achievement of a specific research and development milestone. Following this transaction, Burkly's direct ownership in Editas Medicine now totals 78,193 shares.
Gilmore O'Neill, CEO and Director of Editas Medicine, Inc., vested 43,567 shares of common stock on November 5, 2026. This vesting was a result of achieving a specific research and development milestone tied to a performance-based restricted stock unit award granted in March 2024. Following this transaction, O'Neill directly owns 286,756 shares of Editas Medicine common stock.
Editas Medicine (NASDAQ:EDIT) shares have fallen below their 200-day moving average, trading at $2.55, below the $2.68 average. Despite the price drop, analyst sentiment remains a "Moderate Buy" with an average price target of $5.83. The company also reported better-than-expected quarterly earnings and revenue.